Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer. [PDF]
Clin Transl Oncol, 2023 Zuo B +8 more
europepmc +3 more sources
JAMA Network Open, 2023 Key Points Question Are sodium-glucose cotransporter 2 inhibitors (SGLT2Is) associated with risk of incident obstructive airway disease (OAD) and exacerbation events in clinical settings among patients with type 2 diabetes compared with dipeptidyl ...
P. Au +7 more
semanticscholar +1 more source
JAMA Network Open, 2022 This cohort study assesses whether treatment with glucagon-like peptide-1 (GLP-1) receptor agonists is associated with better outcomes than treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes and advanced-stage ...
Jia-Jin Chen +12 more
semanticscholar +1 more source
Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. [PDF]
PLoS ONE, 2016 Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients. In this study, we characterized in vitro properties of trelagliptin, which exhibited approximately 4- and 12 ...
Charles E Grimshaw +11 more
doaj +1 more source
medRxiv, 2021 This study aimed to compare the rates of major cardiovascular adverse events in sodium‐glucose cotransporter‐2 inhibitors (SGLT2I) and dipeptidyl peptidase‐4 inhibitors (DPP4I) users in a Chinese population.
Jiandong Zhou +11 more
semanticscholar +1 more source
Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes [PDF]
Diabetes & Metabolism Journal, 2013 BackgroundThe aims of this study are to investigate the glycemic efficacy and predictive parameters of vildagliptin therapy in Korean subjects with type 2 diabetes.MethodsIn this retrospective study, we retrieved data for subjects who were on twice-daily
Jin-Sun Chang +8 more
doaj +1 more source
Endocrinology, Diabetes & Metabolism, 2021 Objective Sulfonylureas and dipeptidyl peptidase‐4 inhibitors have a multidirectional effect on pancreatic cells. We aimed to evaluate the effects of these drugs on β‐ and α‐cells in rats aged 12 months with type 2 diabetes mellitus when administered in ...
Tuchina Taisiia Pavlovna +7 more
doaj +1 more source
Late Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritis
Journal of Nepal Health Research Council, 2021 Drug-induced arthritis is not an uncommon scenario. DPP-4 inhibitors could potentially cause adverse-events mediated by cytokine-induced inflammation leading to arthritis. The activity of the DPP-4 enzyme could be inversely related to the development of
Binit Vaidya +3 more
doaj +1 more source
Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]
, 2014 The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen +58 more
core +7 more sources
Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells : a randomised, double-blind placebo-controlled feasibility trial [PDF]
, 2020 Background: Recurrent pregnancy loss (RPL) is associated with the loss of endometrial mesenchymal stem-like progenitor cells (eMSC). DPP4 inhibitors may increase homing and engraftment of bone marrow-derived cells to sites of tissue injury.
Brighton, Paul (Paul J.) +13 more
core +1 more source